13 Biotechnology Stocks to Buy Now

The grades of 13 Biotechnology stocks are better this week, according to the Portfolio Grader database. Every one of these stocks has an “A” (“strong buy”) or “B” overall (“buy”) rating.

This week, China Biologic Products, Inc.’s (CBPO) ratings are up from a C last week to a B. China Biologic Products, Inc. is a biopharmaceutical company that engages in the research, development, manufacture, and sale of human plasma-based biopharmaceutical products to hospitals and inoculation centers. The company also gets A’s in return on equity. For more information, get Portfolio Grader’s complete analysis of CBPO stock.

Spark Therapeutics, Inc. (ONCE) shows solid improvement this week. The company’s rating rises from a C to a B. For more information, get Portfolio Grader’s complete analysis of ONCE stock.

The rating of Xencor, Inc. (XNCR) moves up this week, rising from a C to a B. The company also gets A’s in sales growth, earnings momentum, and return on equity. For more information, get Portfolio Grader’s complete analysis of XNCR stock.

This is a strong week for Exact Sciences Corporation (EXAS). The company’s rating climbs to B from the previous week’s C. Exact Sciences Corporation is a molecular diagnostics company, focuses on developing a molecular diagnostic technology for the early detection and prevention of colorectal pre-cancer and cancer. The company also gets A’s in sales growth and earnings revisions. For more information, get Portfolio Grader’s complete analysis of EXAS stock.

XBiotech, Inc. (XBIT) gets a higher grade this week, advancing from a C last week to a B. The company also gets A’s in earnings revisions. For more information, get Portfolio Grader’s complete analysis of XBIT stock.

Exelixis, Inc.’s (EXEL) ratings are looking better this week, moving up to a A from last week’s B. Exelixis, Inc. is a development-stage biotechnology company dedicated to the discovery and development of small-molecule therapeutics for the treatment of cancer and other serious diseases. The company also gets A’s in sales growth, earnings revisions, and earnings surprise. For more information, get Portfolio Grader’s complete analysis of EXEL stock.

Lion Biotechnologies, Inc. (LBIO) is seeing ratings go up from a C last week to a B this week. The company also gets A’s in earnings revisions. For more information, get Portfolio Grader’s complete analysis of LBIO stock.

Invitae Corp. (NVTA) earns a B this week, jumping up from last week’s grade of C. The company also gets A’s in sales growth and earnings momentum. For more information, get Portfolio Grader’s complete analysis of NVTA stock.

MediciNova, Inc. (MNOV) improves from a B to a A rating this week. MediciNova, Inc. acquires, develops, and commercializes small molecule therapeutics. For more information, get Portfolio Grader’s complete analysis of MNOV stock.

This week, Aurinia Pharmaceuticals Inc. (AUPH) pushes up from a C to a B rating. For more information, get Portfolio Grader’s complete analysis of AUPH stock.

Amarin Corporation Plc Sponsored ADR (AMRN) boosts its rating from a C to a B this week. Amarin Corporation Plc Sponsored ADR focuses on developing the treatment for cardiovascular disease in the field of lipid science. The company also gets A’s in sales growth, earnings surprise, and earnings momentum. For more information, get Portfolio Grader’s complete analysis of AMRN stock.

Rigel Pharmaceuticals, Inc. (RIGL) gets a higher grade this week, advancing from a D last week to a B. Rigel Pharmaceuticals, Inc. is a clinical-stage drug development company that discovers and develops novel, small-molecule drugs for the treatment of inflammatory and autoimmune diseases, as well as muscle disorders. The company also gets A’s in sales growth and earnings surprise. For more information, get Portfolio Grader’s complete analysis of RIGL stock.

The rating of MEI Pharma, Inc. (MEIP) moves up this week, rising from a C to a B. MEI Pharma, Inc. is an oncology company focused on the clinical development of novel therapeutics targeting cancer metabolism. For more information, get Portfolio Grader’s complete analysis of MEIP stock.

Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.


Article printed from InvestorPlace Media, https://investorplace.com/2016/08/13-biotechnology-stocks-to-buy-now-2/.

©2020 InvestorPlace Media, LLC